Scientists reported discovery of a class of potent neutralizing antibodies that target the Marburg virus and cross‑neutralize the closely related Ravn virus. The work, published in npj Viruses, identifies antibody epitopes with broad reactivity, informing both therapeutic antibody development and vaccine antigen design. The team characterized neutralization potency, epitope mapping and in vitro breadth, highlighting candidates suitable for rapid therapeutic development in outbreak scenarios. Preclinical efficacy and manufacturability remain next steps. Public‑health agencies and biodefense programs will likely prioritize these antibodies as potential emergency countermeasures while industry seeks routes to clinical translation and scalable production.